source
- Biotech firms must align operating models with their unique DNA, not rely on generic SMID templatesThe article points out that two biotech firms with similar head counts, pipelines and growth plans can operate very differently. One may build extensive internal development infrastructure, while t…
- UniQure tumbles with latest data for Huntington’s gene therapyAnalysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of "AMT-130."BioPharma Dive · 1mo ago↗ source
- Kodiak Sciences' Phase 3 eye drug data beats Regeneron’s Eylea, shares double